Background: GLP1s are ineffective for a subset of patients. Differentiating between responders and non-responders based on baseline variables would allow for an individualized approach to managing diabetes.

Methods: A retrospective analysis of 324 veterans at the Omaha VA with type 2 diabetes on a GLP1 agonist to evaluate effectiveness quantified by reductions in HbA1c (>/= 0.5%) body weight (>/= 3%) and insulin doses (>/= 10% decrease or off insulin) relative to baseline was done with the outcome being a complete response in all three. Associations between categorical variables of interest and the dichotomous outcome were assessed using Chi-Square and t-tests. A logistic regression was run for the dichotomous outcome and included variables with bivariate p-values less than 0.20.

Results: In terms of, response to one, two or all outcome variables, Dulaglutide had, 22 (38.6%) , 21 (36.8%) and 9 (15.8%) ; Liraglutide had 45 (34.6%) , 44 (33%) and 33 (25.3%) ; Semaglutide had 24 (17.5%) , 64 (46.7%) and 43 (31.4%) . Patients on Semaglutide trended towards having higher odds of a complete response (odds 2.45 95% CI 0.93, 6.48) compared to Dulaglutide. Older patients had a higher odds of a complete response (odds 1.95% CI 1.01, 1.p=0.02 Table 1) . Variables including baseline A1c, insulin dose, BMI, Metformin, and eGFR were not significantly associated with a complete response to GLP1.

Conclusion: Age and the type of GLP1 are variables that determine effectiveness.


S.Kunwar: None. K.Samson: None. C.Davis: None. V.Shivaswamy: Research Support; Eli Lilly and Company, Kowa Company, Ltd., Novo Nordisk. C.Desouza: Advisory Panel; AstraZeneca, Bayer AG, Novo Nordisk A/S, Consultant; Asahi Kasei Corporation.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at